Physician profile
Quang Phan
NPI 1982698957
$63,529.66
in general payments reported to CMS, 2019-2025
25 companies · $7,862 in 2025
The $7,862 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,105 · 2021: $11K · 2022: $9,212 · 2023: $8,409 · 2024: $12K · 2025: $7,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $4,722 · Travel and Lodging: $1,249 · Gift: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,070.00 |
| Food and Beverage | $4,722.45 |
| Travel and Lodging | $1,249.49 |
| Gift | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58,041.07 | 2019-2025 | Vemlidy, Livdelzi |
| Lilly USA, LLC | $953.82 | 2019-2024 | Taltz, Omvoh |
| Abbvie INC. | $759.45 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $675.13 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $473.34 | 2020-2024 | Sutab |
| Galderma Laboratories, L.P. | $269.09 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $252.41 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.31 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $199.85 | 2019-2023 | Rebyota |
| Exact Sciences Corporation | $152.08 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $142.84 | 2025 | Barrx |
| Madrigal Pharmaceuticals | $137.90 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $132.40 | 2021-2025 | Overstitch Endoscopic Suturing System |
| Csa Medical, INC | $130.99 | 2019 | |
| Redhill Biopharma INC. | $128.02 | 2020-2024 | Talicia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $124.88 | 2025 | Zenpep |
| Leo Pharma INC. | $121.62 | 2025 | Adbry |
| Genzyme Corporation | $120.39 | 2022 | |
| Lucid Diagnostics INC. | $118.61 | 2022 | |
| Apollo Endosurgery US INC | $111.07 | 2023 | Overstitch Endoscopic Suturing System |
| Celltrion USA INC. | $94.88 | 2025 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $77.82 | 2024-2025 | Voquezna |
| Albireo Pharma, INC. | $57.55 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $24.80 | 2021 | |
| Intra-Sana Laboratories | $24.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quang Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.